1-9 of 9
Lang Zhou
Close
Sort by
Journal Articles

Updated Outcomes from the Historical Control Study SCHOLAR-3 Contextualizing ZUMA-3 Results of Brexucabtagene Autoleucel (KTE-X19) in Adult Patients with Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia (R/R B-ALL)

Bijal D. Shah, Armin Ghobadi, Olalekan O. Oluwole, Aaron C. Logan, Nicolas Boissel, Ryan D. Cassaday, Thibaut Leguay, Michael R. Bishop, Max S. Topp, Dimitrios Tzachanis, Kristen M. O'Dwyer, Martha L. Arellano, Yi Lin, Maria R. Baer, Gary J. Schiller, Jae H Park, Marion Subklewe, Mehrdad Abedi, Monique C. Minnema, William G. Wierda, Daniel J. DeAngelo, Patrick Stiff, Deepa Jeyakumar, Jinghui Dong, Sabina Adhikary, Lang Zhou, Petra C. Schuberth, Imi Faghmous, Behzad Kharabi Masouleh, Roch Houot
Journal: Blood
Blood (2022) 140 (Supplement 1): 3158–3161.
https://doi.org/10.1182/blood-2022-158248
Published: 2022
Journal Articles

Safety and Efficacy of Venetoclax in Combination with Navitoclax in Adult and Pediatric Relapsed/Refractory Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma

Norman J. Lacayo, MD, Vinod A. Pullarkat, MD, Wendy Stock, MD, Elias Jabbour, MD, Ashish Bajel, MBBS, FRACP, FRCPA, Jeffrey Rubnitz, MD PhD, Jessica Leonard, MD, Charles G. Mullighan, MBBS, MD, Seong Lin Khaw, MD, Susan I. Vear, MD MSCI, Joseph T. Opferman, PhD, Ahmed Hamed Salem, PhD FCP, Michelle Schmidt, Bo Tong, PhD, Lang Zhou, PhD, Jeremy A. Ross, PhD, Lindsey Bensman, Amanda Jacobson, PhD, Robin Norris, MD MS, MPH, Thomas Alexander, MDMPH
Journal: Blood
Blood (2019) 134 (Supplement_1): 285.
https://doi.org/10.1182/blood-2019-126977
Published: 2019
Journal Articles

Identification of Recurrent Genomic Alterations in the Apoptotic Machinery in CLL Patients Treated with Venetoclax Monotherapy

Brenda J Chyla, PhD, Relja Popovic, PhD, Charles Lu, PhD, Fengjiao Dunbar, PhD, Danjuma Quarless, PhD, Kenneth Robinson, MS, Scott Warder, PhD, Amanda Jacobson, PhD, Lang Zhou, PhD, Andrew Souers, PhD, Jeffrey Waring, PhD, Anahita Bhathena, PhD, Joel D. Leverson, PhD, Su Young Kim, MD PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 172.
https://doi.org/10.1182/blood-2019-127458
Published: 2019
Journal Articles

Efficacy of venetoclax in relapsed chronic lymphocytic leukemia is influenced by disease and response variables

Clinical Trials & Observations
Andrew W. Roberts, Shuo Ma, Thomas J. Kipps, Steven E. Coutre, Matthew S. Davids, Barbara Eichhorst, Michael Hallek, John C. Byrd, Kathryn Humphrey, Lang Zhou, Brenda Chyla, Jacqueline Nielsen, Jalaja Potluri, Su Young Kim, Maria Verdugo, Stephan Stilgenbauer, William G. Wierda, John F. Seymour
Journal: Blood
Blood (2019) 134 (2): 111–122.
https://doi.org/10.1182/blood.2018882555
Published: 2019
Includes: Supplemental data
Journal Articles

Minimal Residual Disease Status with Venetoclax Monotherapy Is Associated with Progression-Free Survival in Chronic Lymphocytic Leukemia

William G. Wierda, MD PhD, Andrew W. Roberts, MBBS, PhD, Paolo Ghia, MD PhD, Jennifer R. Brown, MD PhD, Stephan Stilgenbauer, Florence Cymbalista, MD, Nicole Lamanna, MD, John F. Seymour, MBBS, PhD, Sebastian Böttcher, MD, Madlaina Breuleux, PhD DAS, Brenda Chyla, Lang Zhou, PhD, Jacqueline Nielsen, PhD, Su Young Kim, MD PhD, Jalaja Potluri, MD, Johnathan C. Maher, PhD, Peter Hillmen, MB ChB, PhD FRCP, FRCPath
Journal: Blood
Blood (2018) 132 (Supplement 1): 3134.
https://doi.org/10.1182/blood-2018-99-110183
Published: 2018
Journal Articles

Venetoclax for patients with chronic lymphocytic leukemia who progressed during or after idelalisib therapy

Clinical Trials & Observations
Steven Coutre, Michael Choi, Richard R. Furman, Herbert Eradat, Leonard Heffner, Jeffrey A. Jones, Brenda Chyla, Lang Zhou, Suresh Agarwal, Tina Waskiewicz, Maria Verdugo, Rod A. Humerickhouse, Jalaja Potluri, William G. Wierda, Matthew S. Davids
Journal: Blood
Blood (2018) 131 (15): 1704–1711.
https://doi.org/10.1182/blood-2017-06-788133
Published: 2018
Includes: Supplemental data
Journal Articles

Impact of Number of Prior Therapies and Bulk of Disease on Outcomes with Venetoclax (VEN) Monotherapy for Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)

William G Wierda, MD PhD, John F Seymour, MBBS, PhD, Andrew W. Roberts, Su Young Kim, L. Leanne Lash-Fleming, Johnathan Maher, Todd Busman, Lang Zhou, Jacqueline Nielsen, Stephan Stilgenbauer, MD PhD
Journal: Blood
Blood (2017) 130 (Supplement 1): 4329.
https://doi.org/10.1182/blood.V130.Suppl_1.4329.4329
Published: 2017
Journal Articles

Analysis of PET-CT to Identify Richter's Transformation in 167 Patients with Disease Progression Following Kinase Inhibitor Therapy

Anthony R. Mato, MD, William G Wierda, MD PhD, Matthew S. Davids, MD, Bruce D. Cheson, MD, Steven Coutre, MD, Michael Choi, MD, Richard R. Furman, Leonard Heffner, MD, Paul M. Barr, MD, Herbert Eradat, Lang Zhou, Maria Verdugo, MD, Jalaja Potluri, Jeffrey Jones, MD
Journal: Blood
Blood (2017) 130 (Supplement 1): 834.
https://doi.org/10.1182/blood.V130.Suppl_1.834.834
Published: 2017
Journal Articles

Venetoclax (VEN) Is Active in Chronic Lymphocytic Leukemia (CLL) Relapsed or Refractory to More Than One B-Cell Receptor Pathway Inhibitor (BCRi)

William G Wierda, MD PhD, Matthew S. Davids, MD, Richard R. Furman, Bruce D. Cheson, MD, Paul M. Barr, MD, Herbert Eradat, Leonard Heffner, MD, Jeffrey Jones, MD, Lang Zhou, Maria Verdugo, MD, Rod A. Humerickhouse, Jalaja Potluri, Michael Choi, MD
Journal: Blood
Blood (2017) 130 (Supplement 1): 3025.
https://doi.org/10.1182/blood.V130.Suppl_1.3025.3025
Published: 2017